Sesen Bio, Inc. (NASDAQ:SESN) marched up 24.6% compared to a 52-week low price of $0.66. The shares were last seen trading 7.55% higher, taking the closing price at $0.82 on 02/08/2019. At recent session, the prices were hovering between $0.7601 and $0.8338. This company shares are 357.32% off its target price of $3.75 and the current market capitalization stands at $63.43M. The recent change has given its price a -25.5% deficit over SMA 50 and -76.47% deficit over its 52-week high. The stock witnessed 0.41% gains, -47.21% declines and -46.53% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SESN’s volatility during a week at 8.43% and during a month it has been found around 8.29%.Sesen Bio, Inc. (SESN) Top Holders
Institutional investors currently hold around $31 million or 54.2% in SESN stock. Look at its top three institutional owners. Consonance Capital Management Lp owns $6.2 million in Sesen Bio, Inc., which represents roughly 9.77% of the company’s market cap and approximately 20% of the institutional ownership. Similar statistics are true for the second largest owner, Venbio Select Advisor Llc, which owns 6,800,000 shares of the stock are valued at $5.6 million. The third largest holder is Trv Gp, Llc, which currently holds $3.99 million worth of this stock and that ownership represents nearly 6.29% of its market capitalization.Sesen Bio, Inc. 13F Filings
At the end of September reporting period, 24 institutional holders increased their position in Sesen Bio, Inc. (NASDAQ:SESN) by some 3,991,344 shares, 28 decreased positions by 6,730,327 and 10 held positions by 26,766,482. That puts total institutional holdings at 37,488,153 shares, according to SEC filings. The stock grabbed 13 new institutional investments totaling 3,208,766 shares while 15 institutional investors sold out their entire positions totaling 4,019,216 shares.Sesen Bio, Inc. (NASDAQ:SESN) Insider Trades
Multiple company employees have indulged in significant insider trading. Sesen Bio, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CFO Mccabe John J has sold 1,399 shares of Sesen Bio, Inc. (SESN) in trading session dated Feb. 14, 2017. These shares are worth $2,938 and were traded at $2.1 each. The SEC filing shows that Celniker Abbie performed a sale of 10,031 shares. The Director disposed these shares by way of transaction on Sep. 28, 2016. The company’s shares were given away at $3 per share worth to an income of some $30,093 on account of Celniker Abbie.
10% Owner, Flagship Ventures Fund 2007, L, sold 443,422 common shares of Sesen Bio, Inc. (SESN) in the open market. In a transaction dated Sep. 23, 2016, the shares were put up for sale at an average price of $3.16, raking in a sum of $1,401,214. After this sale, 1,833,802 common shares of SESN are directly owned by the insider, with total stake valued at $1,503,718.
In the transaction dated Sep. 21, 2016, the great number of shares disposed came courtesy the 10% Owner; Flagship Ventures Fund 2007, L disposed a total of 386,340 shares at an average price of $3.69, amounting to approximately $1,425,595. The insider now directly owns 1,833,802 shares worth $1,503,718.Sesen Bio, Inc. (SESN) Analyst Guide
Several analysts have released their opinion on Sesen Bio, Inc. (NASDAQ:SESN), with 2 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.75 average brokerage recommendation.